Viking Therapeutics
VKTX
143 hedge funds and large institutions have $319M invested in Viking Therapeutics in 2019 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 39 increasing their positions, 45 reducing their positions, and 24 closing their positions.
46% more call options, than puts
Call options by funds: $16M | Put options by funds: $11M
14% more capital invested
Capital invested by funds: $280M → $319M (+$39M)
4% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 24
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less funds holding
Funds holding: 144 → 143 (-1)
1.32% less ownership
Funds ownership: 56.37% → 55.05% (-1.3%)
13% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 45
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$4.97M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$4.3M |
| 3 |
WG
Winton Group
London,
United Kingdom
|
+$2.87M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$2.41M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$1.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.6M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$4.54M |
| 3 |
Jennison Associates
New York
|
-$3.19M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.88M |
| 5 |
State Street
Boston,
Massachusetts
|
-$1.83M |
VKTX Hedge Fund Activity: Q4 2019 in Review
143 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q4 2019, worth a combined $319M — up 14% from $280M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new VKTX positions and 24 closed out — a net gain of 1 holder — while 39 added to existing stakes and 45 trimmed.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $4.97M. The largest seller was Fidelity Investments, cutting an estimated $5.6M.
- 143 institutional investors held Viking Therapeutics (VKTX) as of Q4 2019, down from 144 in Q3 2019.
- Funds reported $319M of Viking Therapeutics stock for Q4 2019, up 14% quarter-over-quarter.
- 25 funds opened new Viking Therapeutics positions in Q4 2019 and 24 closed out, a net change of +1 holder.
- The largest Viking Therapeutics buyer in Q4 2019 was ArrowMark Colorado Holdings, an estimated $4.97M added.
- The largest Viking Therapeutics seller in Q4 2019 was Fidelity Investments, an estimated $5.6M sold.
Based on aggregated 13F filings for Q4 2019.